Fulltext

Utility of pre-treatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as prognostic factors in breast cancer

Koh CH 1 , Bhoo-Pathy N 2 , Ng KL 3 , Jabir RS 3 , Tan GH 3 , See MH 3 Show all authors , Jamaris S 3 , Taib NA 3

Affiliations 

  • 1 1] Department of Surgery, Faculty of Medicine, University of Malaya, 50603 Lembah Pantai, Kuala Lumpur, Malaysia [2] Department of Surgery, Hospital Tengku Ampuan Afzan, Jalan Besar, 25100 Kuantan, Pahang, Malaysia
  • 2 1] Julius Center University of Malaya, Faculty of Medicine, University of Malaya, 50603 Lembah Pantai, Kuala Lumpur, Malaysia [2] National Clinical Research Centre, Hospital Kuala Lumpur, Level 3, Dermatology Block, 50586 Jalan Pahang, Kuala Lumpur, Malaysia [3] Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, 3508 GA Utrecht, The Netherlands
  • 3 Department of Surgery, Faculty of Medicine, University of Malaya, 50603 Lembah Pantai, Kuala Lumpur, Malaysia
Br. J. Cancer, 2015 Jun 30;113(1):150-8.
PMID: 26022929 DOI: 10.1038/bjc.2015.183

Abstract

Peripheral blood-derived inflammation-based scores such as the neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) have recently been proposed as prognostic markers in solid tumours. Although evidence to support these markers as unfavourable prognostic factors is more compelling in gastrointestinal cancers, very little is known of their impact on breast cancer. We investigated the association between the NLR and PLR, and overall survival after breast cancer.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications